Retargeting of herpes simplex virus (HSV) vectors

Current Opinion in Virology

Volumn 21, Issue , 2016, Pages 93-101

  Goins, William F ^a   Hall, Bonnie ^a   Cohen, Justus B ^a   Glorioso, Joseph C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CELL SURFACE RECEPTOR; COAT PROTEIN; GLYCOPROTEIN D; HEPARAN SULFATE; HERPES SIMPLEX VIRUS VECTOR; HERPESVIRUS ENTRY MEDIATOR; LIGAND; NECTIN 1; NECTIN 1ALPHA; NECTIN 2; NECTIN 2ALPHA; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS RECEPTOR; VIRUS VECTOR; DRUG CARRIER;

HERPES SIMPLEX VIRUS; HOST RANGE; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS PARTICLE; GENE THERAPY; GENE VECTOR; GENETICS; PHARMACOKINETICS; PHYSIOLOGY; PROCEDURES; SIMPLEXVIRUS; VIRAL TROPISM;

DRUG CARRIERS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; SIMPLEXVIRUS; VIRAL TROPISM;

EID: 84985987046     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2016.08.007     Document Type: Review

References (71)

1. 1 Salmon, F., Grosios, K., Petry, H., Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera(R)). Expert Rev Clin Pharmacol 7 (2014), 53–65.
2. 2 Yla-Herttuala, S., Endgame: glybera finally recommended for approval as the first gene therapy drug in the european union. Mol Ther 20 (2012), 1831–1832.
3. 3 Andtbacka, R.H., Kaufman, H.L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K.A., Spitler, L.E., Puzanov, I., Agarwala, S.S., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33 (2015), 2780–2788.
4. 4 Andtbacka, R.H., Ross, M., Puzanov, I., Milhem, M., Collichio, F., Delman, K.A., Amatruda, T., Zager, J.S., Cranmer, L., Hsueh, E., et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the optim phase III clinical trial. Ann Surg Oncol, 2016, 10.1245/s10434-016-5286-0 {Epub ahead of print}.
5. 5 Pol, J., Kroemer, G., Galluzzi, L., First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology, 5, 2016, e1115641, 10.1080/2162402X.2015.1115641.
6. 6•• Gatta, V., Petrovic, B., Campadelli-Fiume, G., The engineering of a novel ligand in gH confers to HSV an expanded tropism independent of gD activation by its receptors. PLoS Pathog, 11, 2015, e1004907, 10.1371/journal.ppat.1004907 This paper was the first report of insertion of the retargeting sequences, the HER2 scFv, into gH both in the background of wild-type and detargeted gD. Infection of SK-OV-3 ovarian tumor cells in culture could be completely blocked using herceptin antibody against HER2. This suggests that gD–receptor interaction can be abrogated as long as specific binding still occurs via gH.
7. 7•• Leoni, V., Gatta, V., Palladini, A., Nicoletti, G., Ranieri, D., Dall'Ora, M., Grosso, V., Rossi, M., Alviano, F., Bonsi, L., et al. Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases. Oncotarget 6 (2015), 34774–34787 This work employed a completely detargeted/retargeted oHSV with the scFv to HER2 inserted in the 60–218 amino acid deleted region of gD. In animal tumor studies the virus inhibited lung and brain metastases when the virus was delivered in mesenchymal stem cell (MSCs) as carriers.
8. 8• Zhou, G., Roizman, B., Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor. Proc Natl Acad Sci U S A 103 (2006), 5508–5513 This work details the retargeting of the IL-13 receptor using an HSV recombinant virus in which the IL-13 ligand was introduced into the HS-binding region of gC as well as the N-terminus of gD that had been completely detargeted from the native gD receptors. The same ligand inserted into two different HSV glycoproteins could help aid in retargeting.
9. 9•• Shibata, T., Uchida, H., Shiroyama, T., Okubo, Y., Suzuki, T., Ikeda, H., Yamaguchi, M., Miyagawa, Y., Fukuhara, T., Cohen, J.B., et al. Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread. Gene Ther 23 (2016), 479–488 This manuscript highlights the use of a completely gD receptor detargeted oHSV possessing the gB:N/T ROE mutations that enable efficient retargeting to EpCAM-bearing or EGFR-bearing tumor cells depending on the scFv employed. The EpCAM-retargeted oHSV will not infect and kill glioma tumors (EGFR+) while the EGFR-retargeted virus is unable to infect and lyse the colon cancer tumors (EpCAM+) further enforcing the specifcity of the retargeting.
10. 10•• Uchida, H., Marzulli, M., Nakano, K., Goins, W.F., Chan, J., Hong, C.S., Mazzacurati, L., Yoo, J.Y., Haseley, A., Nakashima, H., et al. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol Ther 21 (2013), 561–569 This was the first report using the gB:N/T (D285N/A549T) compensatory ROE mutations in combination of a fully detargeted/retargeted gD to achieve efficient killing of human GBM30 glioma cell tumors in nude mice even assessed by MRI. Biodistribution analysis using this detargeted/EGFR-retargeted oHSV demonstrated the homing of the virus to the tumor volume in tumor-bearing compared to normal mice when administered by intravenious tail vein injection further attesting to specificity.
11. 11 Eisenberg, R.J., Atanasiu, D., Cairns, T.M., Gallagher, J.R., Krummenacher, C., Cohen, G.H., Herpes virus fusion and entry: a story with many characters. Viruses 4 (2012), 800–832.
12. 12 Karasneh, G.A., Shukla, D., Herpes simplex virus infects most cell types in vitro: clues to its success. Virol J, 8, 2011, 10.1186/1743-422X-8-481.
13. 13 Spear, P.G., Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol 6 (2004), 401–410.
14. 14 Laquerre, S., Anderson, D.B., Stolz, D.B., Glorioso, J.C., Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J Virol 72 (1998), 9683–9697.
15. 15 Cai, W.H., Gu, B., Person, S., Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion. J Virol 62 (1988), 2596–2604.
16. 16 Desai, P.J., Schaffer, P.A., Minson, A.C., Excretion of non-infectious virus particles lacking glycoprotein H by a temperature-sensitive mutant of herpes simplex virus type 1: evidence that gH is essential for virion infectivity. J Gen Virol 69:Pt 6 (1988), 1147–1156.
17. 17 Hutchinson, L., Browne, H., Wargent, V., Davis-Poynter, N., Primorac, S., Goldsmith, K., Minson, A.C., Johnson, D.C., A novel herpes simplex virus glycoprotein, gL, forms a complex with glycoprotein H (gH) and affects normal folding and surface expression of gH. J Virol 66 (1992), 2240–2250.
18. 18 Ligas, M.W., Johnson, D.C., A herpes simplex virus mutant in which glycoprotein D sequences are replaced by beta-galactosidase sequences binds to but is unable to penetrate into cells. J Virol 62 (1988), 1486–1494.
19. 19 Herold, B.C., Visalli, R.J., Susmarski, N., Brandt, C.R., Spear, P.G., Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulphate and glycoprotein B. J Gen Virol 75:Pt 6 (1994), 1211–1222.
20. 20 Laquerre, S., Argnani, R., Anderson, D.B., Zucchini, S., Manservigi, R., Glorioso, J.C., Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread. J Virol 72 (1998), 6119–6130.
21. 21 Trybala, E., Bergstrom, T., Svennerholm, B., Jeansson, S., Glorioso, J.C., Olofsson, S., Localization of a functional site on herpes simplex virus type 1 glycoprotein C involved in binding to cell surface heparan sulphate. J Gen Virol 75:Pt 4 (1994), 743–752.
22. 22 Oh, M.J., Akhtar, J., Desai, P., Shukla, D., A role for heparan sulfate in viral surfing. Biochem Biophys Res Commun 391 (2010), 176–181.
23. 23 Montgomery, R.I., Warner, M.S., Lum, B.J., Spear, P.G., Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87 (1996), 427–436.
24. 24 Geraghty, R.J., Krummenacher, C., Cohen, G.H., Eisenberg, R.J., Spear, P.G., Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 280 (1998), 1618–1620.
25. 25 Shukla, D., Liu, J., Blaiklock, P., Shworak, N.W., Bai, X., Esko, J.D., Cohen, G.H., Eisenberg, R.J., Rosenberg, R.D., Spear, P.G., A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 99 (1999), 13–22.
26. 26 Tiwari, V., O'Donnell, C., Copeland, R.J., Scarlett, T., Liu, J., Shukla, D., Soluble 3-O-sulfated heparan sulfate can trigger herpes simplex virus type 1 entry into resistant chinese hamster ovary (CHO-K1) cells. J Gen Virol 88:Pt 4 (2007), 1075–1079.
27. 27 Atanasiu, D., Whitbeck, J.C., Cairns, T.M., Reilly, B., Cohen, G.H., Eisenberg, R.J., Bimolecular complementation reveals that glycoproteins gB and gH/gL of herpes simplex virus interact with each other during cell fusion. Proc Natl Acad Sci U S A 104 (2007), 18718–18723.
28. 28 Uchida, H., Shah, W.A., Ozuer, A., Frampton, A.R. Jr., Goins, W.F., Grandi, P., Cohen, J.B., Glorioso, J.C., Generation of herpesvirus entry mediator (HVEM)-restricted herpes simplex virus type 1 mutant viruses: Resistance of HVEM-expressing cells and identification of mutations that rescue nectin-1 recognition. J Virol 83 (2009), 2951–2961.
29. 29 Whitbeck, J.C., Peng, C., Lou, H., Xu, R., Willis, S.H., Ponce de Leon, M., Peng, T., Nicola, A.V., Montgomery, R.I., Warner, M.S., Soulika, A.M., et al: Glycoprotein, D., of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry. J Virol 71 (1997), 6083–6093.
30. 30 Yoon, M., Zago, A., Shukla, D., Spear, P.G., Mutations in the N termini of herpes simplex virus type 1 and 2 gDs alter functional interactions with the entry/fusion receptors HVEM, nectin-2, and 3-O-sulfated heparan sulfate but not with nectin-1. J Virol 77 (2003), 9221–9231.
31. 31 Cocchi, F., Fusco, D., Menotti, L., Gianni, T., Eisenberg, R.J., Cohen, G.H., Campadelli-Fiume, G., The soluble ectodomain of herpes simplex virus gD contains a membrane-proximal pro-fusion domain and suffices to mediate virus entry. Proc Natl Acad Sci U S A 101 (2004), 7445–7450.
32. 32 Zhou, G., Roizman, B., Separation of receptor-binding and profusogenic domains of glycoprotein D of herpes simplex virus 1 into distinct interacting proteins. Proc Natl Acad Sci U S A 104 (2007), 4142–4146.
33. 33 Connolly, S.A., Jackson, J.O., Jardetzky, T.S., Longnecker, R., Fusing structure and function: a structural view of the herpesvirus entry machinery. Nat Rev Microbiol 9 (2011), 369–381.
34. 34 Di Giovine, P., Settembre, E.C., Bhargava, A.K., Luftig, M.A., Lou, H., Cohen, G.H., Eisenberg, R.J., Krummenacher, C., Carfi, A., Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1. PLoS Pathog, 7, 2011, e1002277, 10.1371/journal.ppat.1002277.
35. 35 Carfi, A., Willis, S.H., Whitbeck, J.C., Krummenacher, C., Cohen, G.H., Eisenberg, R.J., Wiley, D.C., Herpes simplex virus glycoprotein D bound to the human receptor HveA. Mol Cell 8 (2001), 169–179.
36. 36 Krummenacher, C., Supekar, V.M., Whitbeck, J.C., Lazear, E., Connolly, S.A., Eisenberg, R.J., Cohen, G.H., Wiley, D.C., Carfi, A., Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry. EMBO J 24 (2005), 4144–4153.
37. 37• Gallagher, J.R., Saw, W.T., Atanasiu, D., Lou, H., Eisenberg, R.J., Cohen, G.H., Displacement of the C terminus of herpes simplex virus gD is sufficient to expose the fusion-activating interfaces on gD. J Virol 87 (2013), 12656–12666 This paper details the overall change in gD structure post receptor binding to the gD amino terminus that leads to the displacement of the C-terminus as a way of communicating the fusion signal to the gB–gH/gL complex.
38. 38• Lazear, E., Whitbeck, J.C., Zuo, Y., Carfi, A., Cohen, G.H., Eisenberg, R.J., Krummenacher, C., Induction of conformational changes at the N-terminus of herpes simplex virus glycoprotein D upon binding to HVEM and nectin-1. Virology 448 (2014), 185–195 This paper details a comparison of the mutational analyses of the HVEM and Nectin-1 binding domains of gD with the actual crystal structure of receptor-bound and free gD. It provides a greater understanding of the conformational change in gD upon engaging the two different cellular gD receptors.
39. 39 Atanasiu, D., Whitbeck, J.C., de Leon, M.P., Lou, H., Hannah, B.P., Cohen, G.H., Eisenberg, R.J., Bimolecular complementation defines functional regions of herpes simplex virus gB that are involved with gH/gL as a necessary step leading to cell fusion. J Virol 84 (2010), 3825–3834.
40. 40 Chowdary, T.K., Cairns, T.M., Atanasiu, D., Cohen, G.H., Eisenberg, R.J., Heldwein, E.E., Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL. Nat Struct Mol Biol 17 (2010), 882–888.
41. 41 Parry, C., Bell, S., Minson, T., Browne, H., Herpes simplex virus type 1 glycoprotein H binds to alphavbeta3 integrins. J Gen Virol 86:Pt 1 (2005), 7–10.
42. 42 Gianni, T., Salvioli, S., Chesnokova, L.S., Hutt-Fletcher, L.M., Campadelli-Fiume, G., Alphavbeta6- and alphavbeta8-integrins serve as interchangeable receptors for HSV gH/gL to promote endocytosis and activation of membrane fusion. PLoS Pathog, 9, 2013, e1003806, 10.1371/journal.ppat.1003806.
43. 43 Saitoh, T., Arii, J., Suenaga, T., Wang, J., Kogure, A., Uehori, J., Arase, N., Shiratori, I., Tanaka, S., Kawaguchi, Y., et al. PILRalpha is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B. Cell 132 (2008), 935–944.
44. 44 Heldwein, E.E., Lou, H., Bender, F.C., Cohen, G.H., Eisenberg, R.J., Harrison, S.C., Crystal structure of glycoprotein B from herpes simplex virus 1. Science 313 (2006), 217–220.
45. 45• Zeev-Ben-Mordehai, T., Vasishtan, D., Hernandez Duran, A., Vollmer, B., White, P., Prasad Pandurangan, A., Siebert, C.A., Topf, M., Grunewald, K., Two distinct trimeric conformations of natively membrane-anchored full-length herpes simplex virus 1 glycoprotein B. Proc Natl Acad Sci U S A 113 (2016), 4176–4181 This work employs electron cryotomography to examine the differences in pre-fusion and post-fusion crystallographic forms of gB helping to detail the conformational change in gB enabling fusion of the viral envelop with the host cell or endosomal membrane.
46. 46 Roche, S., Bressanelli, S., Rey, F.A., Gaudin, Y., Crystal structure of the low-pH form of the vesicular stomatitis virus glycoprotein G. Science 313 (2006), 187–191.
47. 47 Roche, S., Rey, F.A., Gaudin, Y., Bressanelli, S., Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G. Science 315 (2007), 843–848.
48. 48 Hannah, B.P., Heldwein, E.E., Bender, F.C., Cohen, G.H., Eisenberg, R.J., Mutational evidence of internal fusion loops in herpes simplex virus glycoprotein B. J Virol 81 (2007), 4858–4865.
49. 49 Anderson, D.B., Laquerre, S., Ghosh, K., Ghosh, H.P., Goins, W.F., Cohen, J.B., Glorioso, J.C., Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry. J Virol 74 (2000), 2481–2487.
50. 50 Tang, J., Yang, T., Ghosh, H.P., Geller, A.I., Helper virus-free HSV-1 vectors packaged both in the presence of vsv g protein and in the absence of HSV-1 glycoprotein B support gene transfer into neurons in the rat striatum. J Neurovirol 7 (2001), 548–555.
51. 51 Kwon, H., Bai, Q., Baek, H.J., Felmet, K., Burton, E.A., Goins, W.F., Cohen, J.B., Glorioso, J.C., Soluble V domain of nectin-1/HveC enables entry of herpes simplex virus type 1 (HSV-1) into HSV-resistant cells by binding to viral glycoprotein D. J Virol 80 (2006), 138–148.
52. 52 Nakano, K., Asano, R., Tsumoto, K., Kwon, H., Goins, W.F., Kumagai, I., Cohen, J.B., Glorioso, J.C., Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule. Mol Ther 11 (2005), 617–626.
53. 53 Baek, H., Uchida, H., Jun, K., Kim, J.H., Kuroki, M., Cohen, J.B., Glorioso, J.C., Kwon, H., Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells. Mol Ther 19 (2011), 507–514.
54. 54 Kamiyama, H., Zhou, G., Roizman, B., Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor. Gene Ther 13 (2006), 621–629.
55. 55 Zhou, G., Roizman, B., Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13ralpha2 receptor of malignant glioma cells. J Virol 79 (2005), 5272–5277.
56. 56 Gambini, E., Reisoli, E., Appolloni, I., Gatta, V., Campadelli-Fiume, G., Menotti, L., Malatesta, P., Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma. Mol Ther 20 (2012), 994–1001.
57. 57 Menotti, L., Cerretani, A., Campadelli-Fiume, G., A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors. J Virol 80 (2006), 5531–5539.
58. 58 Menotti, L., Cerretani, A., Hengel, H., Campadelli-Fiume, G., Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J Virol 82 (2008), 10153–10161.
59. 59• Menotti, L., Nicoletti, G., Gatta, V., Croci, S., Landuzzi, L., De Giovanni, C., Nanni, P., Lollini, P.L., Campadelli-Fiume, G., Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc Natl Acad Sci U S A 106 (2009), 9039–9044 This paper employs a gD-detargeted HER2-retargeted oHSV with the scFv to HER2 inserted into the Ig fold of gD (amino acids 61–218). Tumor studies in nude mice showed 60% survival of SK-OV-3 ovarian tumor-bearing mice injected with the virus out to seven months. Moreover, the oHSV proved to be non-toxic in normal nude mice.
60. 60• Nanni, P., Gatta, V., Menotti, L., De Giovanni, C., Ianzano, M., Palladini, A., Grosso, V., Dall'ora, M., Croci, S., Nicoletti, G., et al. Preclinical therapy of disseminated HER-2(+) ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. PLoS Pathog, 9, 2013, e1003155, 10.1371/journal.ppat.1003155 Interperitoneal injection of the HER2 retargeted virus produced an increase in the medium survival time of time of nude mice bearing SK-OV-3 ovarian tumors and 20% survival of mice possessing breast cancer metastases out to 100 days post-injection.
61. 61 Reisoli, E., Gambini, E., Appolloni, I., Gatta, V., Barilari, M., Menotti, L., Malatesta, P., Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice. Cancer Gene Ther 19 (2012), 788–795.
62. 62 Uchida, H., Chan, J., Goins, W.F., Grandi, P., Kumagai, I., Cohen, J.B., Glorioso, J.C., A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection. J Virol 84 (2010), 12200–12209.
63. 63•• Uchida, H., Chan, J., Shrivastava, I., Reinhart, B., Grandi, P., Glorioso, J.C., Cohen, J.B., Novel mutations in gB and gH circumvent the requirement for known gD receptors in herpes simplex virus 1 entry and cell-to-cell spread. J Virol 87 (2013), 1430–1442 Using a novel selection methodology, this work detailed the isolation of viral mutations in gB fusogenic molecule and gH fusion effector gene product that compensated for weak signaling via gD. Thus dependence on a gD–receptor interaction to provide the fusion signal to the gB–gH/gL complex can be compensated by alterations of the amino acid sequences of gB and gH.
64. 64 Cao, H., Zhang, G.R., Wang, X., Kong, L., Geller, A.I., Enhanced nigrostriatal neuron-specific, long-term expression by using neural-specific promoters in combination with targeted gene transfer by modified helper virus-free HSV-1 vector particles. BMC Neurosci, 9, 2008, 10.1186/1471-2202-9-37.
65. 65 Wang, X., Kong, L., Zhang, G.R., Sun, M., Geller, A.I., Targeted gene transfer to nigrostriatal neurons in the rat brain by helper virus-free HSV-1 vector particles that contain either a chimeric HSV-1 glycoprotein C-GDNF or a gC-BDNF protein. Brain Res Mol Brain Res 139 (2005), 88–102.
66. 66 Argnani, R., Boccafogli, L., Marconi, P.C., Manservigi, R., Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide. Gene Ther 11:13 (2004), 1087–1098.
67. 67 Grandi, P., Wang, S., Schuback, D., Krasnykh, V., Spear, M., Curiel, D.T., Manservigi, R., Breakefield, X.O., HSV-1 virions engineered for specific binding to cell surface receptors. Mol Ther 9 (2004), 419–427.
68. 68 Grandi, P., Fernandez, J., Szentirmai, O., Carter, R., Gianni, D., Sena-Esteves, M., Breakefield, X.O., Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells. Cancer Gene Ther 17 (2010), 655–663.
69. 69 Cao, H., Zhang, G.R., Geller, A.I., Antibody-mediated targeted gene transfer to NMDA NR1-containing neurons in rat neocortex by helper virus-free HSV-1 vector particles containing a chimeric HSV-1 glycoprotein C-staphylococcus A protein. Brain Res 1351 (2010), 1–12.
70. 70 Cao, H., Zhang, G.R., Geller, A.I., Antibody-mediated targeted gene transfer of helper virus-free HSV-1 vectors to rat neocortical neurons that contain either NMDA receptor 2B or 2A subunits. Brain Res 1415 (2011), 127–135.
71. 71 Conner, J., Braidwood, L., Brown, S.M., A strategy for systemic delivery of the oncolytic herpes virus HSV1716: Redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein. Gene Ther 15 (2008), 1579–1592.